Assignment history

Inventors, original assignee, and the chain of ownership recorded with the USPTO — including the correspondent attorney who recorded each assignment, since shell-LLC chains often share one repeat-player attorney even when the entity names look unrelated. Surfaces NPE / patent-troll patterns: shell-entity transfers, known asserters in the chain, repeat correspondent fingerprints, pre-litigation assignments, and bankruptcy fire-sales.

Assignment history

Inventors

Robert D. Gordon (Veloxis Pharmaceuticals Inc.)
Per Holm (Veloxis Pharmaceuticals Inc.)
Anne-Marie Lademann (Veloxis Pharmaceuticals Inc.)
Tomas Norling (Veloxis Pharmaceuticals Inc.)

No unusual patterns noted; all inventors appear to have been employed by the original assignee at the time of filing.

Original Assignee

Veloxis Pharmaceuticals Inc.
Veloxis Pharmaceuticals Inc. is a pharmaceutical company focused on the development and commercialization of therapeutics for transplant patients. Their primary product embodying the claims of this patent is Envarsus XR (tacrolimus extended-release tablets). Veloxis Pharmaceuticals Inc. is currently operating.

Assignment Timeline

No assignments for US11110081 were found on the USPTO Assignment Center.

Timeline Diagram

timeline
    title Ownership of US 11110081
    2020 : Filed by Veloxis Pharma Inc
    2021 : Issued to Veloxis Pharma Inc

NPE / troll-pattern signals

Shell-entity transfer — not present
Known asserter in the chain — not present
Repeat correspondent across the chain — not present
Cascading transfers — not present
Pre-litigation transfer — not present
Bankruptcy fire-sale — not present
Privateering — not present
Defensive aggregator (anti-NPE) — not present

Verdict

Insufficient data. There are no recorded assignments for US11110081 on the USPTO Assignment Center, indicating that the patent is likely still owned by the original assignee, Veloxis Pharmaceuticals Inc.

USPTO Assignment Center search page for US11110081: https://assignmentcenter.uspto.gov/#!/patent/11110081